Monte Rosa Therapeutics Inc

NASDAQ GLUE

Download Data

Monte Rosa Therapeutics Inc Debt to Tangible Net Worth Ratio 1 year YoY Change (%) for the quarter ending September 19, 2024

Monte Rosa Therapeutics Inc Debt to Tangible Net Worth Ratio 1 year YoY Change (%) is NA for the quarter ending September 19, 2024. The debt to tangible net worth ratio measures the level of debt relative to a company's tangible net worth. It is calculated by dividing total debt by the difference between shareholders' equity and intangible assets (such as goodwill). This ratio provides insights into the company's financial leverage, excluding intangible assets. A higher ratio suggests a higher level of debt burden in relation to tangible net worth. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: GLUE

Monte Rosa Therapeutics Inc

CEO Dr. Markus Warmuth M.D.
IPO Date June 24, 2021
Location United States
Headquarters 645 Summer Street, Boston, MA, United States, 02210
Employees 130
Sector Healthcare
Industry Biotechnology
Description

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1"/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

NKTX

Nkarta Inc

NA

NA

GBIO

Generation Bio Co

NA

NA

DSGN

Design Therapeutics Inc

NA

NA

HOWL

Werewolf Therapeutics Inc

NA

NA

STOK

Stoke Therapeutics Inc

NA

NA

GRCL

Gracell Biotechnologies Inc.

NA

NA

THRX

Theseus Pharmaceuticals Inc

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email